MedTrace Logo

Utilization of TEG to Monitor Rivaroxaban Activity

NCT02651909 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2019-11-08

No results posted yet for this study

Summary

The invesigators seek to devise a strategy for the assessment of Rivaroxaban activity in trauma and Emergency General Surgery (EGS) patients available as point-of-care testing.

Thromboelastography (TEG) is a point of care, viscoelastic measurement of coagulation that is widely used in trauma and is viewed by many as superior to standard coagulation studies for the assessment of coagulopathy following injury and may be useful in detecting rivaroxaban effect in trauma and EGS patients to assess the degree of functional factor Xa impairment.

Conditions

Interventions

OTHER

blood sampling

blood sampling for TEG analysis, Thrombin time, thrombin generation, PT with neoplastine, ecarin chromogenic assay, anti-factor Xa (rivaroxaban assay

Sponsors & Collaborators

  • Janssen Scientific Affairs, LLC

    collaborator INDUSTRY

  • Matthew Neal MD

    lead OTHER

Principal Investigators

  • Matthew D Neal, MD · University of Pittsburgh, Division of Trauma and Acute Care Surgery Department of Surgery

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-30
Primary Completion
2018-07-07
Completion
2019-11-04

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02651909 on ClinicalTrials.gov